K-numberK241516
Device nameBTL-398
ApplicantBTL Industries, Inc.
Product codeKPI
Device classClass II
Decision dateFeb 10, 2025
DecisionSubstantially Equivalent
Regulation876.5320
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The BTL-398 is a non-invasive therapeutic device that delivers magnetic pulses to stimulate pelvic floor muscles for treating urinary incontinence in adults. It consists of a main unit with electromagnetic field generators and a microprocessor-controlled touch-screen interface, plus a chair applicator with an adjustable magnetic coil. Therapy is administered through clothing and can last up to 30 minutes.

Technological characteristics

The BTL-398 adds two new features compared to the predicate HPM-6000UF: (1) Dynamic HIFEM Technology (DHT) enabling horizontal coil position adjustment of ±100mm, and (2) Pressure Wave Technology (PWT) using air circulation through the seat cushion at 0-100% intensity and up to 40 Hz repetition rate. Both devices share identical magnetic field intensity (0.7–2.5 T), pulse parameters (280 µs, dual-phase sine pulses, 1–150 Hz), therapy modes, and operating specifications.

Test standards cited

IEC 60601-1:2020 (Medical electrical equipment—Basic safety and essential performance); IEC 60601-1-2:2020 (Electromagnetic compatibility requirements and tests); FDA Guidance (2023) on Content of Premarket Submissions for Device Software Functions. Performance bench testing included magnetic field strength, coil surface temperature, and PWT feature validation.

Substantial equivalence argument

Both devices target the same indication (male and female urinary incontinence), employ identical therapeutic principles (initiating nerve action potentials to cause muscle contraction), use the same magnetic field specifications and therapy modes, and are prescription-use chair-based systems for professional healthcare settings. The DTH and PWT features are ancillary positioning and comfort enhancements that do not alter the fundamental electromagnetic stimulation mechanism or safety profile. Performance testing confirmed the subject device met all acceptance criteria, demonstrating that the technological differences do not raise new safety or effectiveness questions.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →